Exact Sciences' $56 Mil. IPO Readies Firm For Colorectal Cancer Screen Trial

Exact Sciences will use about $19 mil. of its $56 mil. initial public offering to fund a 5,300-patient, 40-center clinical trial evaluating genomics-based diagnostics to screen for colorectal cancer.